In a meta-analysis including 11,086 patients with hematological malignancies evaluating SARS-CoV-2 vaccine antibody responses, significantly impaired responses were observed in individuals receiving Ruxolitinib or BTK inhibitors [26]. Here, BTK is linked to hematologic disorder.